Drug Trial Radar · NCT07081646
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
91
Planned (sponsor's estimate)
Start
Aug 18, 2025
Primary completion
Aug 15, 2029
Study completion Feb 14, 2031
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Conditions
- Relapsed AL Amyloidosis
- Refractory AL Amyloidosis
- Light Chain Amyloidosis
- Amyloidosis
Interventions
AZD0120Drug
Participants will receive AZD0120 via intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants With incidence and severity of Treatment-emergent Adverse EventsTime frame: Through study completion, a minimum of 6 months
- Phase 2: Proportion of Participants Achieving Complete ResponseTime frame: Through study completion, a minimum of 6 months
Locations
18 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
Tampa, Florida · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Calgary, Alberta, Canada · Withdrawn
Research Site
Calgary, Alberta, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Withdrawn
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
London, United Kingdom · Withdrawn
Research Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.